Doctors and researchers at the University of Michigan have a longstanding record of innovation and excellence in endocrine medicine, specifically relating to adrenal cancer. Their preeminence in the field dates back six decades to the appointment of Dr. Jerome Conn as director of the U-M Metabolism Research Unit in 1943. Dr. Conn was the first to identify a type of adrenal tumor now known as Conn’s syndrome. Subsequent pioneering efforts in the medical and surgical treatment of adrenal tumors led to the formation of U-M’s first adrenal clinic in the 1970’s. The legacy of leadership provides the backdrop for the impressive advances in adrenal cancer research and patient care that continues at the University of Michigan.
Michigan is one of the few centers in the country with a Multidisciplinary Adrenal Cancer Clinic. Cases are reviewed by a team of adrenal cancer specialists from disciplines including surgery, medical oncology, endocrinology, radiation oncology, pathology, nuclear medicine, nursing and social work, ensuring optimal patient care. By the time patients are seen in the clinic, all films, pathology and lab reports have already been reviewed, allowing for a comprehensive visit followed by presentation of the case to the tumor board and consensus treatment planning the same day.
The Endocrine Oncology Program at the University of Michigan Comprehensive Cancer Center has been recognized regionally, nationally and internationally as a leader in both patient care and research. In 2008, the program was named a Blue Distinction Center for Complex and Rare Cancers by the Blue Cross and Blue Shield Association. This designation, based on rigorous and evidence-based selection criteria, further reinforces Michigan’s position of leadership in diagnosing adrenal cancer. With only 16 faculty members in six specialties, the UMCCC Endocrine Oncology Program is the only fully-integrated, interdisciplinary clinic for thyroid and adrenal patients in the world.
For all of the above reasons, Draper Therapies is proud to partner directly with the University of Michigan to support their excellence and endeavors in the field of adrenal cancer.
Please see the attached document for the formal letter of approval signifying our partnership with the University of Michigan’s Comprehensive Cancer Research Program.